

SEP-17-02 13:50

FROM-GEN-PROBE EXECUTIVE OFFICE

8584108922

T-101 P-04/34 F-166

IT 20  
RAY  
9-24-02

PTO/SB/22 (10-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR EXTENSION OF TIME UNDER 37 C.F.R. § 1.136(a)		Docket Number (Optional) GP068-03.CN1								
<table border="1"> <tr> <td colspan="2">In re Application of <b>BECKER et al.</b></td> </tr> <tr> <td>Application Number <b>09/523,237</b></td> <td>Filed <b>March 10, 2000</b></td> </tr> <tr> <td colspan="2">For <b>KITS FOR AMPLIFYING TARGET NUCLEIC ACID SEQUENCES USING MODIFIED OLIGONUCLEOTIDES</b></td> </tr> <tr> <td>Group Art Unit <b>1635</b></td> <td>Examiner <b>Lacourriere, K.</b></td> </tr> </table>			In re Application of <b>BECKER et al.</b>		Application Number <b>09/523,237</b>	Filed <b>March 10, 2000</b>	For <b>KITS FOR AMPLIFYING TARGET NUCLEIC ACID SEQUENCES USING MODIFIED OLIGONUCLEOTIDES</b>		Group Art Unit <b>1635</b>	Examiner <b>Lacourriere, K.</b>
In re Application of <b>BECKER et al.</b>										
Application Number <b>09/523,237</b>	Filed <b>March 10, 2000</b>									
For <b>KITS FOR AMPLIFYING TARGET NUCLEIC ACID SEQUENCES USING MODIFIED OLIGONUCLEOTIDES</b>										
Group Art Unit <b>1635</b>	Examiner <b>Lacourriere, K.</b>									

This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.

The requested extension and appropriate non-small-entity fee are as follows  
(check time period desired):

<input type="checkbox"/> One month (37 CFR 1.17(a)(1))	\$ _____
<input checked="" type="checkbox"/> Two months (37 CFR 1.17(a)(2))	\$ <u>400.00</u>
<input type="checkbox"/> Three months (37 CFR 1.17(a)(3))	\$ _____
<input type="checkbox"/> Four months (37 CFR 1.17(a)(4))	\$ _____
<input type="checkbox"/> Five months (37 CFR 1.17(a)(5))	\$ _____

Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee amount shown above is reduced by one-half, and the resulting fee is: \$ \_\_\_\_\_.

A check in the amount of the fee is enclosed.

Payment by credit card. Form PTO-2038 is attached.

The Commissioner has already been authorized to charge fees in this application to a Deposit Account.

The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number 07-0835, in the name of Gen-Probe Incorporated.

I am the  applicant/inventor

assignee of record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

attorney or agent of record.

attorney or agent under 37 CFR 1.34(a).  
Registration number if acting under 37 CFR 1.34(a) \_\_\_\_\_.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

September 17, 2002

Date

Signature

Charles B. Cappellari, Reg No. 40,937

Typed or printed name

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

Total of \_\_\_\_\_ forms are submitted.

**Burden Hour Statement:** This form is estimated to take 0.1 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patent Law Enforcement, U.S. Patent and Trademark Office, Washington, DC 20231. 070835

09523237

01 FC:116

400.00 CH